|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2022
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
V10XX05
|
|
gptkbp:brand
|
gptkb:Pluvicto
|
|
gptkbp:CASNumber
|
2451266-41-4
|
|
gptkbp:chemicalFormula
|
C60H74LuN14O14
|
|
gptkbp:clinicalTrialPhase
|
gptkb:VISION_trial
|
|
gptkbp:contains
|
lutetium-177
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:developer
|
gptkb:Novartis
|
|
gptkbp:drugClass
|
radiopharmaceutical
therapeutic radiopharmaceutical
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:genericName
|
gptkb:lutetium_(177Lu)_vipivotide_tetraxetan
|
|
gptkbp:halfLife
|
6.7 days (for lutetium-177)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pluvicto
|
|
gptkbp:indication
|
treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketingAuthorizationHolder
|
gptkb:Novartis
|
|
gptkbp:mechanismOfAction
|
radioligand therapy
|
|
gptkbp:pregnancyCategory
|
not for use in pregnancy
|
|
gptkbp:prescriptionRequired
|
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
gptkb:lymphopenia
nausea
vomiting
diarrhea
abdominal pain
constipation
fatigue
urinary tract infection
back pain
weight loss
thrombocytopenia
dry mouth
leukopenia
decreased appetite
|
|
gptkbp:storage
|
2°C to 8°C
|
|
gptkbp:target
|
gptkb:PSMA
|
|
gptkbp:UNII
|
6Q1K1Q1K0E
|
|
gptkbp:usedFor
|
prostate cancer
|
|
gptkbp:bfsParent
|
gptkb:NOVN
|
|
gptkbp:bfsLayer
|
5
|